| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab175489-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $119.90 | |
| Ab175489-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $559.90 | |
| Ab175489-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,399.90 | |
| Ab175489-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,239.90 |
Purity≥90% (SDS-PAGE&SEC-HPLC); Endotoxin Level<1.0 EU/mg; Mouse IgG2a & Rat IgG2b; CHO; ELISA, Flow Cytometry, Functional assay, Animal Model; Unconjugated
| Product Name | Catumaxomab (anti-CD3&EpCAM) - Primary antibody, specific to CD3E; EPCAM, Mouse IgG2a, Antibody of CD3e |
|---|---|
| Synonyms | CD3 epsilon antibody | CD3e antibody | CD3e antigen antibody | CD3e antigen epsilon polypeptide (TiT3 complex) antibody | CD3E antigen epsilon polypeptide antibody | CD3E antigen, epsilon subunit antibody | CD3e molecule epsilon antibody | CD3e molecule, |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, ≥90%(SDS-PAGE&SEC-HPLC), See COA |
| Biochemical and Physiological Mechanisms | CD3: The CD3 complex mediates signal transduction. EpCAM: May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier |
| Host species | Mouse; Rat |
| Specificity | CD3E; EPCAM |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | CROSS-LINKING AGENT |
| Mechanism of action | Antibody of CD3e |
| Product Description | Catumaxomab (anti-CD3&EpCAM), a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab (anti-CD3&EpCAM) region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab (anti-CD3&EpCAM) can be used for anti-tumor research, especially epithelial cancers. |
| Isotype | Mouse IgG2a |
|---|---|
| Light Chain Type | Mouse kappa & Rat lambda2b |
| SDS-PAGE | 146.73 kDa |
| Purification Method | Protein A purified |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 509077-98-9 |
Catumaxomab (anti-CD3&EpCAM) (Ab175489) - Flow Cytometry
Flow Cytometry analysis of Jurkat cells labelling CD3 (red) with Catumaxomab (anti-CD3&EpCAM) (Ab175489) at 1.0 μg/mL for 1 hour at 4°C. Goat Anti-Mouse IgG (PE) (Ab179006) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Catumaxomab (anti-CD3&EpCAM) (Ab175489) - ELISA
Immobilized Recombinant Human EpCAM protein (rp170132) at 1.0 μg/mL can bind Catumaxomab (anti-CD3&EpCAM) (Ab175489) with the EC₅₀ of 66.05 ng/mL.
Catumaxomab (anti-CD3&EpCAM) (Ab175489) - SEC
The purity of Catumaxomab (anti-CD3&EpCAM) (Ab175489) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| 1. Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H. (1999) Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing.. J Immunol, 163 (3): (1246-52). [PMID:10415020] [10.1021/op500134e] |
| 2. Riesenberg R, Buchner A, Pohla H, Lindhofer H. (2001) Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).. J Histochem Cytochem, 49 (7): (911-7). [PMID:11410615] [10.1021/op500134e] |
| 3. Ruf P, Lindhofer H. (2001) Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody.. Blood, 98 (8): (2526-34). [PMID:11588051] [10.1021/op500134e] |
| 4. Shen J, Zhu Z. (2008) Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer.. Curr Opin Mol Ther, 10 (3): (273-84). [PMID:18535935] [10.1021/op500134e] |
| 5. Sebastian M, Passlick B, Friccius-Quecke H, Jäger M, Lindhofer H, Kanniess F, Wiewrodt R, Thiel E, Buhl R, Schmittel A. (2007) Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.. Cancer Immunol Immunother, 56 (10): (1637-44). [PMID:17410361] [10.1021/op500134e] |
| 6. Linke R, Klein A, Seimetz D. (2010) Catumaxomab: clinical development and future directions.. MAbs, 2 (2): (129-36). [PMID:20190561] [10.1021/op500134e] |
| 7. Chelius D, Ruf P, Gruber P, Plöscher M, Liedtke R, Gansberger E, Hess J, Wasiliu M, Lindhofer H. (2010) Structural and functional characterization of the trifunctional antibody catumaxomab.. MAbs, 2 (3): (309-19). [PMID:20418662] [10.1021/op500134e] |
